- Natera: A global leader in cell-free DNA testing
Natera advances molecular diagnostics with integrity and scientific rigor, and supports integration of information provided by our tests into health care decision making
- Natera Acquires Foresight Diagnostics - Morningstar
Natera, Inc (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) detection, today
- Natera buys Foresight Diagnostics in $450M cancer testing deal
Natera is looking to grow its portfolio of tools to detect the recurrence of cancer with a deal to acquire Foresight Diagnostics, the Stanford University spinout and developer of blood tests for
- Natera Buys Foresight Diagnostics for Up to $450 Million
Natera said it has acquired Foresight Diagnostics in a deal valued at up to $450 million, bolstering the company's portfolio of minimal residual disease, or MRD, testing products
- Natera acquires Foresight Diagnostics for $275 million - MSN
Natera is a global leader in cell-free DNA and precision medicine, focusing on oncology, women’s health, and organ health The company aims to integrate personalized genetic testing and
- Whats Going On With Natera Stock Friday? - Benzinga
Natera, Inc (NASDAQ: NTRA) on Friday acquired Foresight Diagnostics, a cancer diagnostics company, for $275 million upfront with an additional $175 million in earnouts tied to the achievement of
- Natera Acquires Foresight Diagnostics | Contract Pharma
Natera Inc , a cell-free DNA and precision medicine company, has acquired Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) detection
- Portal Hub - Natera
Visit the appropriate Natera™ portal to check on results, schedule conversations with genetic counselors, place orders, or make payments
|